Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 8
Submit an article Journal homepage
723
Views
3
CrossRef citations to date
0
Altmetric
Letter to the Editor

Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity

Nikoletta LendvaiDepartment of Medicine, Myeloma Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; ;Department of Medicine, Weill Medical College of Cornell University, New York, NY, USA; Correspondence[email protected]
View further author information
,
Ioanna TsakosDepartment of Medicine, Myeloma Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; View further author information
,
Sean M. DevlinDepartment of Biostatistics and Epidemiology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; View further author information
,
Wendy L. SchafferDepartment of Medicine, Weill Medical College of Cornell University, New York, NY, USA; ;Department of Medicine, Cardiology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; View further author information
,
Hani HassounDepartment of Medicine, Myeloma Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; ;Department of Medicine, Weill Medical College of Cornell University, New York, NY, USA; View further author information
,
Alexander M. LesokhinDepartment of Medicine, Myeloma Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; ;Department of Medicine, Weill Medical College of Cornell University, New York, NY, USA; ORCID Iconhttp://orcid.org/0000-0001-9321-702XView further author information
ORCID Icon,
Heather LandauDepartment of Medicine, Weill Medical College of Cornell University, New York, NY, USA; ;Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; ORCID Iconhttp://orcid.org/0000-0002-3152-1189View further author information
ORCID Icon,
Neha KordeDepartment of Medicine, Myeloma Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; ;Department of Medicine, Weill Medical College of Cornell University, New York, NY, USA; View further author information
,
Sham MailankodyDepartment of Medicine, Myeloma Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; ;Department of Medicine, Weill Medical College of Cornell University, New York, NY, USA; View further author information
,
Eric SmithDepartment of Medicine, Myeloma Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; ;Department of Medicine, Weill Medical College of Cornell University, New York, NY, USA; View further author information
,
David J. ChungDepartment of Medicine, Weill Medical College of Cornell University, New York, NY, USA; ;Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; View further author information
,
Guenther KoehneDepartment of Medicine, Weill Medical College of Cornell University, New York, NY, USA; ;Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; View further author information
,
Gunjan L. ShahDepartment of Medicine, Weill Medical College of Cornell University, New York, NY, USA; ;Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; View further author information
,
Aeri AlexanderDepartment of Medicine, Myeloma Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; View further author information
,
Minal PatelSloan Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; View further author information
,
Andrea BallagiOlink Bioscience, Uppsala, SwedenView further author information
,
Ida GrundbergOlink Bioscience, Uppsala, SwedenView further author information
,
Sergio A. GiraltDepartment of Medicine, Weill Medical College of Cornell University, New York, NY, USA; ;Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; View further author information
&
Ola LandgrenDepartment of Medicine, Myeloma Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; ;Department of Medicine, Weill Medical College of Cornell University, New York, NY, USA; ORCID Iconhttp://orcid.org/0000-0001-6485-4839View further author information
ORCID Icon show all
Pages 1981-1985 | Received 27 Jun 2017, Accepted 31 Oct 2017, Published online: 08 Jan 2018

References

  • Atrash S, Tullos A, Panozzo S, et al. Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib. Blood Cancer J. 2015;5:e272.
  • Grandin EW, Ky B, Cornell RF, et al. Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma. J Card Fail. 2015;21:138–144.
  • Danhof S, Schreder M, Rasche L, et al. ‘Real-life’ experience of preapproval carfilzomib-based therapy in myeloma – analysis of cardiac toxicity and predisposing factors. Eur J Haematol. 2016;97:25–32.
  • Siegel D, Martin T, Nooka A, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica, 2013;98:1753–1761.
  • Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142–152.
  • Chari A, Hajje D. Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring. BMC Cancer. 2014;14:915.
  • Chen-Scarabelli C, Corsetti G, Pasini E, et al. Spasmogenic effects of the proteasome inhibitor carfilzomib on coronary resistance, vascular tone and reactivity. EBioMedicine. 2017;21:206–212.
  • Rosenthal A, Luthi J, Belohlavek M, et al. Carfilzomib and the cardiorenal system in myeloma: an endothelial effect? Blood Cancer J. 2016;6:e384.
  • Lendvai N, Hilden P, Devlin S, et al. A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma. Blood. 2014;124:899–906.
  • Assarsson E, Lundberg M, Holmquist G, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS One. 2014;9:e95192.
  • Jordan A, Roldan V, Garcia M, et al. Matrix metalloproteinase-1 and its inhibitor, TIMP-1, in systolic heart failure: relation to functional data and prognosis. J Intern Med. 2007;262:385–392.
  • Tanaka N, Masamura K, Yoshida M, et al. A role of heparin-binding epidermal growth factor-like growth factor in cardiac remodeling after myocardial infarction. Biochem Biophys Res Commun. 2002;297:375–381.
  • Mikhael J. Management of carfilzomib-associated cardiac adverse events. Clin Lymphoma Myeloma. 2016;16:241–245.
  • Jakubowiak AJ, DeCara JM, Mezzi K. Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies. Hematology. 2017;22:585–591.
  • Wang M, Cheng J. Overview and management of cardiac and pulmonary adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib. Oncology (Williston Park). 2013;27(Suppl 3):24–30.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.